2024 World Conference on Lung Cancer (WCLC) - Posters-P4.14C.03 Real-World Prognostic & Predictive Implications of EORTC & MRS Scores for Immunotherapy and Chemotherapy in Pleural Mesothelioma (PM)

P4.14C.03 Real-World Prognostic & Predictive Implications of EORTC & MRS Scores for Immunotherapy and Chemotherapy in Pleural Mesothelioma (PM)

Back to course

Pdf Summary

The study examines the prognostic and predictive functions of the EORTC Prognostic Score (EPS) and the Mesothelioma Risk Score (MRS) for patients with pleural mesothelioma undergoing immunotherapy or chemotherapy. The analysis, based on data from 326 patients in British Columbia diagnosed between 2010 and 2022, highlights key findings on overall survival (OS) related to treatment type and prognostic score.<br /><br />For patients receiving only chemotherapy, the EPS proved to be a effective prognostic tool, distinguishing between good and poor outcomes. Conversely, for those treated with immunotherapy, the MRS was more efficient at prognosticating outcomes, differentiating between favorable, intermediate, and poor risk groups. This suggests that the MRS may offer predictive insights for immunotherapy over chemotherapy in advanced pleural mesothelioma cases.<br /><br />Notably, EPS-poor patients showed a slightly better OS benefit from immunotherapy compared to EPS-good patients. Additionally, MRS-favorable patients experienced a significantly higher OS advantage from immunotherapy compared to those with intermediate or poor MRS scores.<br /><br />The EPS was originally developed when single-agent chemotherapy was the standard of care, while the MRS was created for patients receiving second-line treatments after platinum-doublet chemotherapy. With evolving treatment options, including immunotherapy, these scoring systems continue to provide valuable insights. However, the current study underscores the greater applicability of MRS for predicting outcomes in the context of immunotherapy.<br /><br />Overall, the findings support the use of EPS for chemotherapy-specific prognostics and underscore a potential role for the MRS in guiding therapy decisions between chemotherapy and immunotherapy. This real-world validation could influence clinical practice, tailoring treatment approaches based on a patient's prognostic score.

Asset Subtitle

Florence Wu

Meta Tag

Speaker Florence Wu

Topic Mesothelioma, Thymoma & Other Thoracic Tumors

Keywords

EORTC Prognostic Score

Mesothelioma Risk Score

pleural mesothelioma

immunotherapy

chemotherapy

overall survival

prognostic tool

predictive insights

treatment outcomes

clinical practice